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A Clinical Scoring System for Selection of Patients
for PTEN Mutation Testing Is Proposed on the Basis
of a Prospective Study of 3042 Probands
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Lisa A. Rybicki,2,3,4 Kresimira Milas,5 Holly Pederson,6 Berna Remzi,7 Mohammed S. Orloff,1,2,3
and Charis Eng1,2,3,5,8,9,*
Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba syndrome are allelic, defined by germline PTEN mutations, and collectively
referred to as PTEN hamartoma tumor syndrome. To date, there are no existing criteria based on large prospective patient cohorts to
select patients for PTENmutation testing. To address these issues, we conducted amulticenter prospective study in which 3042 probands
satisfying relaxed CS clinical criteria were accrued. PTEN mutation scanning, including promoter and large deletion analysis, was per-
formed for all subjects. Pathogenic mutations were identified in 290 individuals (9.5%). To evaluate clinical phenotype and PTEN geno-
type against protein expression, we performed immunoblotting (PTEN, P-AKT1, P-MAPK1/2) for a patient subset (n ¼ 423). In order to
obtain an individualized estimation of pretest probability of germline PTEN mutation, we developed an optimized clinical practice
model to identify adult and pediatric patients. For adults, a semiquantitative score—the Cleveland Clinic (CC) score—resulted in
a well-calibrated estimation of pretest probability of PTEN status. Overall, decreased PTEN protein expression correlated with PTEN
mutation status; decreasing PTEN protein expression correlatedwith increasing CC score (p< 0.001), but not with the National Compre-
hensive Cancer Network (NCCN) criteria (p¼ 0.11). For pediatric patients, we identified highly sensitive criteria to guide PTENmutation
testing, with phenotypic features distinct from the adult setting. Our model improved sensitivity and positive predictive value for germ-
line PTEN mutation relative to the NCCN 2010 criteria in both cohorts. We present the first evidence-based clinical practice model to
select patients for genetics referral and PTEN mutation testing, further supported biologically by protein correlation.Introduction
Cowden syndrome (CS [MIM 158350]), presenting in
adulthood, and Bannayan-Riley-Ruvalcaba syndrome
(BRRS [MIM 153480]),1 a pediatric syndrome, show over-
lapping clinical features and may present with multi-
system disease, including macrocephaly, various cancers,
and skin, neurologic, and gastrointestinal manifesta-
tions.2,3 Because subsets of these two syndromes, together
with other seemingly unrelated clinical syndromes,4 share
a common etiology germline PTEN (MIM 601728) muta-
tion,2 they are allelic and collectively referred to as PTEN
hamartoma tumor syndrome (PHTS).5 Inheritance of this
disorder is autosomal dominant, and penetrance is
believed to be high (around 80%).5 The PTEN tumor
suppressor gene, located on 10q23.3, encodes a dual-spec-
ificity phosphatase that can dephosphorylate both
protein6 and phospholipid substrates.7
We formulated the International Cowden Consortium
(ICC) operational diagnostic criteria8 14 years ago to
select families and affected individuals for purposes of
identifying the specific mutated gene. Over the last 10
years, we have continually revised this set of criteria for1Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH 44195, USA;
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testing,9,10 with early expert opinion and clinical data
derived from families studied from initial consortium
studies suggesting that 85% of patients with CS had an
identifiable PTEN mutation.2,11 The most recent National
Comprehensive Cancer Network (NCCN) 2010 criteria,12
based primarily on these operational criteria, are useful,
but they also have several disadvantages. These include
the inability to quantitatively evaluate individual patients
for their probabilities of testing positive for a PTEN muta-
tion. Additionally, with the multisystem involvement of
Cowden syndrome and rapid expansion of the clinical
spectrum to include phenotypes such as autism13 and
polyposis syndrome,14 the complexity of the current
NCCN criteria involving multiple possible combinations
of major and minor criteria render them challenging for
use outside of a specialist community. Further, the current
NCCN criteria is not refined for adult and pediatric popu-
lations, considering that CS and BRRS are clinically and
epidemiologically distinct as a result of age-related pene-
trance and variable expression, even of the common
underlying PTEN mutation.3 Finally, we note that there
are no existing criteria based on large prospective patient2Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA;
artment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
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Table 1. Operational Criteria for Cowden Syndrome without
Family History of Known PTEN Mutation
Pathognomonic Criteria
Adult Lhermitte-Duclos disease (cerebellar tumors)
Mucocutaneous lesionsa
- Facial trichilemmomas, any numbera (at least two biopsy-proven
trichilemmomasb)
- Acral keratoses
- Papillomatous papules
Mucosal lesions
Autism spectrum disorder and macrocephalyb
Major Criteria
Breast cancer
Thyroid cancer (nonmedullary)
Macrocephaly (megalocephaly) (i.e., 97th percentile and above)
Endometrial cancer
Mucocutaneous lesionsb
- One biopsy-proven trichilemmoma
- Multiple palmoplantar keratoses
- Multifocal cutaneous facial papules
- Macular pigmentation of glans penis
Multiple GI hamartomas or ganglioneuromasb
Minor Criteria
Other thyroid lesions (e.g., adenoma, multinodular goiter)
Mental retardation (i.e., IQ of 75 and below)
Gastrointestinal hamartomasa (single gastrointestinal hamartoma or
ganglioneuromab)
Fibrocystic disease of the breast
Lipomascohorts for selection of patients for PTEN mutation
testing.
Concurrently, advances in the understanding of the
biology of PTEN in a patient-oriented setting have been in-
hibited by the lack of a common reference for measuring
severity of phenotypes arising from PTEN protein defi-
ciency or dysfunction. This is crucial, given insights
supported by increasing laboratory evidence on the impor-
tance of tumor suppressor gene dosage. Small changes in
the expression levels of tumor suppressor genes have
been proposed to influence susceptibility to cancer,15 and
there is experimental support from animal experiments
to support a view that subtle variations of Pten dosage
may also result in increased cancer susceptibility.16 None-
theless, to date, there has been no evidence in the setting
of a human population to support this view. From amolec-
ular angle, as a lipid phosphatase that dephosphorylates
phosphatidylinositol-3,4,5-triphosphate (PIP3) to phos-
phatidylinositol-4,5-phosphate (PIP2), PTEN is the key
negative regulator of the phosphatidylinositol-3-kinase
(PI3K) signal transduction cascade, inhibiting pathways
of growth, proliferation, and survival.17
PTEN inactivation is associated with the activation of the
AKT/mTOR signaling pathway when PTEN’s lipid phospha-
tase ismost relevant andwith themitogen-activated protein
kinase (MAPK) signaling pathways with activatedMAPK1/2
when PTEN’s protein phosphatase pathway is more
relevant.18–20
We thus conducted a prospective multicenter, multina-
tional study, collecting phenotypic data on patients who
met relaxed criteria for CS,21 in order to quantitatively
assess both adult and pediatric patients for a priori risk of
PTEN germline mutation in two large patient cohorts
with a semiquantitative score. Subsequently, we evaluated
whether there was correlation between PTEN protein
dosage and the clinical score.
Fibromas
Genitourinary tumors (especially renal cell carcinoma)
Genitourinary malformationsa
Uterine fibroids
Autism spectrum disorderb
a Present in this section as defined by ICC criteria only.
b Present in this section as defined by NCCN 2010 criteria only.Subjects and Methods
Research Participants
For the two independent cohorts from the Cleveland Clinic (CC)
and The Ohio State University (OSU; C.E., Principal Investigator),
a total of 3042 patients was recruited into a protocol approved by
the Institutional Review Boards for Protection of Human Subjects
from both institutions (CC: 2005–2010; OSU: 2000–2006). Indi-
viduals who were probands and who met relaxed International
Cowden Consortium operational criteria for CS (pathognomonic
criteria, or at least two criteria, either major or minor)9,10 (Table 1)
were recruited prospectively for these cohorts (Table 2). These
patients were recruited from both community and academic
medical centers throughout North America, Europe, and Asia.
Upon providing informed consent, checklists to document pres-
ence or absence of specific features were completed by specialist
genetic counselors or physicians concurrently with submission
of samples. Specialist genetics staff reviewed all checklists and cor-
responded with the enrolling center; if necessary, further primary
documentation of medical records was obtained for phenotype
confirmation with patient consent.The APTEN Mutation and Deletion Analysis
To understand the relationship between PTEN (NM_000314.4)
mutations and the clinical phenotype, we had all subjects undergo
PTEN mutation analysis, as described below. Genomic DNA was
extracted from peripheral blood leukocytes via standard
methods.22 Scanning of genomic DNA samples for PTEN muta-
tions was performed as previously reported with a combination
of denaturing gradient gel electrophoresis, high-resolution
melting curve analysis (Idaho Technology), and direct Sanger
sequencing (ABI 3730xl).23 Deletion analysis with the multiplex
ligation-dependent probe amplification (MLPA) assay24 was per-
formed with the P158 MLPA kit (MRC-Holland) according tomerican Journal of Human Genetics 88, 42–56, January 7, 2011 43
Table 2. Baseline Data for the Study Cohorts
CC Adult
Cohort %
CC
Adult
Mutation
Cohort %
CC
Pediatric
Cohort %
CC Pediatric
Mutation
Cohort %
OSU
Cohort %
PTEN
Mutation
Cohort
(OSU) %
Number 2007 105 92 28 943 157
Age, median (range) 55.9
(18.0–98.2)
43.9
(3.0–78)
8.2
(1.8–16.9)
8.3
(3.0–16.9)
48.5
(1.2–91.7)
36.1
(1.7–73.1)
Gender, male 117 5.8 34 32.4 59 64 21 75 164 17.4 70 44.6
Gender, female 1890 94.2 71 67.6 33 36 7 25 779 82.6 87 55.4
Neurological
Macrocephaly, presence 538 26.8 79 75.2 87 95 28 100 385 40.8 135 86
Extreme macrocephaly
(male, R63 cm)
15 13 11 32 2 3 2 10
Extreme macrocephaly
(female, R60 cm)
67 4 24 34 4 12 2 29
Lhermitte Duclos disease 17 0.8 9 8.6 1 1 0 0 24 2.5 9 5.7
Autism or developmental
delay
41 2 13 12.4 78 85 23 82 115 12.2 34 21.7
Breast and Gynecological
Invasive breast cancer
<30 29 1.5 1 1.4 0 0 0 0 7 0.9 2 2.3
30–39 164 8.7 6 8.5 0 0 0 0 76 9.8 6 6.9
40–49 475 25.1 13 18.3 0 0 0 0 160 20.5 10 11.5
R50 625 33.1 14 19.7 0 0 0 0 179 23 8 9.2
Fibrocystic breast disease 849 44.9 30 42.3 0 0 0 0 269 34.5 23 26.4
Endometrial cancer 74 9.5 12 13.8
<30 11 0.6 1 1.4 0 0 0 0 2 0.3 1 1.1
30–39 23 1.2 2 2.8 0 0 0 0 7 0.9 3 3.4
40–49 50 2.6 5 7 0 0 0 0 21 2.7 7 8
R50 171 9 5 7 0 0 0 0 44 5.6 1 1.1
Fibroids 794 42 27 38 0 0 0 0 290 37.2 18 20.7
Gastrointestinal
Colorectal cancer
<30 2 0.1 0 0 0 0 0 0 0 0 0 0
30–39 3 0.1 1 1 0 0 0 0 1 0.1 0 0
40–49 15 0.7 3 2.9 0 0 0 0 5 0.5 2 1.3
R50 33 1.6 2 1.9 0 0 0 0 10 1.1 0 0
Polyposis syndrome (R5) 74 3.7 36 34.3 2 2 2 7 168 17.8 51 32.5
Intestinal hamartoma, single 23 1.1 16 15.2 5 5 3 11 11 1.2 10 6.4
Intestinal hamartoma,
multiplea
11 0.5 8 7.6 0 0 0 0
Intestinal ganglioneuroma,
single
14 0.7 9 8.6 2 2 2 7 11 1.2 5 3.2
Intestinal ganglioneuroma,
multiplea
10 0.5 7 6.7 0 0 0 0
Glycogenic acanthosis 21 1 16 15.2 1 1 1 4 14 1.5 9 5.7
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Table 2. Continued
CC Adult
Cohort %
CC
Adult
Mutation
Cohort %
CC
Pediatric
Cohort %
CC Pediatric
Mutation
Cohort %
OSU
Cohort %
PTEN
Mutation
Cohort
(OSU) %
Skin
Trichilemmomas, biopsy
proven
13 0.6 6 5.7 0 0 0 0 112 11.9 39 24.8
Oral papillomas 160 8 16 15.2 3 3 1 4 210 22.3 72 45.9
Penile freckling 22 18.8 10 29.4 16 27 5 24 61 37.2 38 54.3
Acral keratoses 128 6.4 28 26.7 5 5 2 7 54 5.7 16 10.2
Arteriovenous malformations 19 0.9 12 11.4 4 4 2 7 14 1.5 10 6.4
Skin lipomas 528 26.3 45 42.9 25 27 13 46 336 35.6 89 56.7
Fibromas 121 6 17 16.2 0 0 0 0 2 0.2 1 0.6
Endocrine
Thyroid cancer
<20 18 0.9 5 4.8 2 2 0 0 11 1.2 3 1.9
20–29 56 2.8 3 2.9 0 0 0 0 16 1.7 1 0.6
30–39 116 5.8 7 6.7 0 0 0 0 58 6.2 4 2.5
40–49 149 7.4 8 7.6 0 0 0 0 45 4.8 3 1.9
R50 203 10.1 4 3.8 0 0 0 0 74 7.8 1 0.6
Thyroid goiter, nodules,
or adenomas
710 35.4 72 68.6 4 4 3 11 182 19.3 48 30.6
Hashimoto’s thyroiditis 151 7.5 22 21 0 0 0 0 19 2 5 3.2
Genitourinary
Renal cell carcinoma 94 4.7 7 6.7 1 1 0 0 43 4.6 5 3.2
Testicular germ cell tumor 4 3.4 2 5.9 0 0 0 0 1 0.6 1 1.4
Ovarian germ cell tumor 5 0.3 2 2.8 0 0 0 0 1 0.1 1 1.1
Congenital genitourinary
malformations
58 2.9 6 5.7 15 16 8 29 14 1.5 2 1.3
a Data on specific head size measurement and exact polyp number are not available in the OSU cohort. For intestinal hamartoma and ganglioneuroma, OSU data
are therefore presented without breakdown.manufacturer’s protocol. All patients underwent resequencing of
the PTEN promoter region as previously described.25 The primers
used are available in Table S1 available online. Promotermutations
were defined as previously reported,11,25 except for 1084T>C;
this variant has been reported in population controls of European
descent (2/150),26 and further work is required to characterize it.Analysis of PTEN and Other Downstream Proteins
by Immunoblotting
Human immortalized lymphoblast-derived cell lines were ob-
tained from each patient and cultured in RPMI-1640 supple-
mented with 20% fetal bovine serum. All cell lines were cultured
at 37C and 5% CO2.
22 Whole-cell lysates were prepared with
Mammalian Protein Extraction Reageant (Pierce) supplemented
with protease inhibitor cocktail (Sigma-Aldrich). Lysates were
separated by SDS-PAGE and transferred onto nitrocellulose. Anti-
bodies used included anti-PTEN mouse monoclonal (Cascade
Biosciences) at 1:5000, anti-phospho-AKT1 rabbit polyclonalThe A(Cell Signaling) at 1:1000, anti-phospho-MAPK1/2 rabbit poly-
clonal (Cell Signaling) at 1:2000, anti-GAPDH rabbit monoclonal
(Cell Signaling) at 1:20,000, and anti-actin mouse monoclonal at
1:20,000. The blots were scanned digitally with the Odyssey
Imaging System (Li-Cor Biotechnology). Detected fluorescence
intensities for protein bands were background adjusted and
normalized between gels with themedian expression of individual
proteins on each blot.Statistical Methods for Score Derivation
and Validation
Risk data for the various phenotypes were obtained from a variety
of sources. For breast, endometrial, and thyroid cancer, age-
adjusted cumulative risk data were drawn from the Surveillance
Epidemiology and End Results database. For other phenotypes,
corresponding prevalence data were derived from the literature,
with North American reports preferred: oral papillomas,27 arterio-
venous malformations,28 autism/developmental delay,29 thyroidmerican Journal of Human Genetics 88, 42–56, January 7, 2011 45
goiter,30 and fibroids.31 Where no standard population-based esti-
mates were available, baseline prevalences were estimated based
on best available expert opinion; where rarity of a feature
precluded reliable estimates, an estimate of 0.01% baseline preva-
lence was used. Patients were classified into adult and pediatric age
groups at a threshold of 18 years of age. Frequency data were
generated from the CC data set, with corresponding relative risks
(RR) calculated relative to baseline population risk. For the pedi-
atric CC data set, a relatively high prevalence of PTEN mutations
allowed ready derivation of highly predictive features from the
relative frequencies of cases, and validation in the external OSU
data set was directly performed. We refer to the criteria developed
here in the pediatric setting as the CC criteria, which is distinct
from the CC score for adults. For the adult data set, which was
considerably larger, derivation of a score was more challenging.
This may be due to a referral bias, which increased recruitment
for patients with oncologic conditions, preventing the use of
conventional regression modeling. Hence, we adopted a clinically
driven modeling approach for data reduction and validation for
weighing adult criteria with the CC data set, validating our
approach in the separate OSU data set.32
We first selected the most predictive phenotypic features at
initial clinical assessment, excluding certain characteristic derma-
tologic features of CS such as fibromas or skin (but not oral) papil-
lomas due to loss of specificity in a community setting. For each
feature, we considered the relative frequency against baseline,
potential for referral bias (most evident in the cancers), and the
prevalence of each feature.Weweighted each featurewith a prespe-
cified approach: an RR relative to baseline of 1–5 corresponded to
a weight of 1; RR of 5–10 with a weight of 2; RR of 10–25 with a
weight of 4; RR of 25–50 with a weight of 6; RR of 50–100 with
a weight of 8; RR > 100 with a weight of 10. High referral bias
for individual features was recognized clinically, being additionally
evident through relatively high RR when comparing prevalences
in the study population relative to the community. We adjusted
the weights for these features empirically through reduction by
one risk tier, except where the weight was already at the lowest
tier of 1, whereupon it was maintained. A score for each individual
was obtained by the sum of weights of all positive features. We
subsequently performed internal validation of this semiquantita-
tive score in the CC and external validation in the OSU adult
data set. All corresponding data fields were available in both data
sets, with the exception of data on extreme macrocephaly and
exact gastrointestinal polyp number in the OSU data set. Conse-
quently, when evaluating the score performance in the OSU data
set, we omitted extreme macrocephaly and matched polyp pres-
ence status with corresponding multiple polyp status. These
changes would be expected to penalize the accuracy of the CC
score relative to the NCCN criteria in the OSU data set; thus, our
validation represents a conservative assessment of the CC score’s
performance. Performance of this score in both data sets was eval-
uated via measurements of sensitivity, specificity, accuracy, posi-
tive and negative predictive value, and receiver-operator character-
istic (ROC) methodology. Likelihood-ratio analysis of each model
nested in a summary model32,33 was performed to compare the
performance of the CC score against the NCCN criteria. Calibra-
tion to obtain bias-corrected estimates of predicted versus
observed values was performed with 200 bootstraps. All analyses
were performed with R 2.11.1.34 For analysis correlating protein
quantitation with PTEN variants, four sample groups were defined
(wild-type, common variants of unknown significance [or SNPs;
>1% prevalence], rare variants of unknown significance [<1%],46 The American Journal of Human Genetics 88, 42–56, January 7, 20and mutations), analysis of variance (ANOVA) testing was used
for comparison between multiple groups, and t tests were used
for two-group comparisons. Linear regression was used in evalu-
ating the association between the CC score and PTEN protein.
All tests were two-sided, and p < 0.05 was deemed significant.Results
PTEN Mutation Spectrum in Patients
Of the 3042 individuals tested, 290 (9.5%) were found to
have germline pathogenic PTEN mutations (Table S2). To
be conservative, we excluded variants of unknown signifi-
cance without proof of functionality from the mutation-
positive group. In total, 85 (29%) missense mutations, 92
(32%) nonsense mutations, 42 (14%) small deletions, 24
(8%) small insertions, 3 (1%) indels, 8 (3%) large deletions,
19 (7%) splice-site donor mutations, 9 (3%) splice-site
acceptor mutations, and 8 (3%) promoter mutations were
found. The mutation spectrum for the 290 probands
(Figure 1) reveals mutations that are distributed irregularly
across all exons, with hot spots in exon 5 (n ¼ 93, 32%),
exon 7 (n ¼ 37, 13%), and exon 8 (n ¼ 45, 16%). A total
of 45 mutations (16%) occurred within the exon 5 hot
spot (aa 123–130), corresponding to the catalytic motif of
the N-terminal phosphatase domain. A total of 101 muta-
tions (35%) occurred within the C2 domain of the PTEN
protein (aa 186–351).
Pediatric Clinical Criteria Derivation
To derive appropriate clinical criteria to guide selection for
PTEN testing, we analyzed genotype and phenotype data
from pediatric (<18 years) and adult individuals separately,
focusing on the CC data set (Table 2) to generate the
criteria for validation testing in the OSU data set. For
pediatric individuals, we determined that the presence of
macrocephaly (occipitofrontal circumference [OFC] > 2
standard deviation [SD] over the population mean, or
97.5th percentile) was a necessary criterion for diagnosis,
based on 100% prevalence at the point of diagnosis
(Table 3). Neurologic (autism and developmental delay)
and dermatologic (lipomas, oral papillomas) features repre-
sented extremely common secondary features; either or
both systems were involved in 100% of patients with
germline PTEN mutation. However, given that dermato-
logic features may often be overlooked, less-prevalent
features in patients at first presentation in the pediatric
setting are likely to be at least as important, such as
vascular (such as arteriovenous) malformations, gastroin-
testinal polyps, thyroid goiter, and early-onset cancers
(thyroid and germ cell).
Adult Clinical Score Derivation
For adults, additional weighing of the criteria was per-
formed, resulting in the derivation of an appropriately
weighted semiquantitative scoring system, referred to
here as the CC score (Table 4). The generated score is useful
for the calculation of point pretest probability of PTEN11
Figure 1. Consolidated PTEN Mutation
Spectrum
Distribution and number of substitutions
(missense and/or nonsense), small inser-
tion mutations, and small deletion muta-
tions across the gene. In the top panel,
blue bars represent missense mutations
and red bars represent nonsense muta-
tions. In the second panel, the blue arrow-
heads represent small deletions and the
red arrowheads represent small insertions
along the gene. Complex mutations
(indels, splice-site mutations, and large
deletions) and promoter mutations are
not depicted. For both panels, frequencies
of both the substitutionmutations and the
insertion/deletion mutations are shown
on the left. The bar below corresponds to
the multiple exons of the PTEN cDNA
molecule, with exon 1 on the left to exon
9 on the right, allowing for matching of
mutation to exon. As evident, exons 5, 7,
and 8 are sites of common mutations.mutation. It is presented together with examples to illus-
trate its use (Figure 2). Increasing risk score was strongly
associated with mutation-positive status (p < 0.001,
Mann-Whitney test). ROC-based analysis demonstrates
the variation of sensitivity and specificity in both data
sets at multiple thresholds (Figures S1 and S2). At
a threshold CC score of 10 (corresponding to a point
pretest probability of approximately 3%; including andTable 3. Pediatric Clinical Criteria for PTEN Testinga
Clinical Features
Percent Prevalence
in CC Data Set
of Pediatric
Probands with PTEN
Mutation
1. Macrocephaly (R2 SD) 100%
2. At least one of the following four
additional criteria should be present:
- Autism or developmental delay 82%
- Dermatologic features, including lipomas,
trichilemmomas, oral papillomas, penile
freckling
60%
- Vascular features, such as arteriovenous
malformations or hemangiomas
29%
- Gastrointestinal polyps 14%
a In addition, pediatric-onset thyroid cancer and germ cell tumors (testicular
cancer and dysgerminoma) are recognized associations of Cowden syndrome
and should provoke consideration of PTEN testing.
The Aabove the threshold score), sensitivity for diagnosis is
90%. Sensitivity falls accordingly as the threshold for CC
score rises, so that when the threshold CC score is 15
(point pretest probability of 10%), the sensitivity is 72%.
We report better performance for our overall approach rela-
tive to the NCCN 2010 criteria via conventional clinical
and epidemiologic measures (Table 5). To evaluate for over-
fitting in the CC score, we used bootstrap validation on the
resulting score within the CC data set (n ¼ 200), demon-
strating excellent calibration (Figure 3) and yielding an
optimism-corrected concordance index of 0.91. Formal
likelihood-ratio testing demonstrated considerably higher
adequacy and strongly significant statistical benefit for
the CC score relative to the NCCN criteria (Figure 4). The
performance of the CC scoring system exceeded that of
the NCCN criteria in cohorts from both centers, consis-
tently showing superior predictive power, concordance
indices, sensitivity, and specificity for the detection of
PTEN mutations relative to the NCCN 2010 criteria.
PTEN Genotype, Clinical Score, and Downstream
Pathway Proteins
We next sought to determine whether there was a correla-
tion between PTEN mutation status and expression of
proteins considered to be downstream readouts for PTEN
signaling. For PTEN mutant patient-derived lymphoblasts
(n¼ 24), PTEN protein was decreased and P-AKT1 was rela-
tively increased (Figure 5) compared to wild-type PTEN,
common variants (SNPs), and rare variants of unknownmerican Journal of Human Genetics 88, 42–56, January 7, 2011 47
Table 4. CC Adult Score Derivation
Population Risk
Relative Risk
(Referral/Community)
Relative Risk
(Mutants/Community) Weight
Neurological
Macrocephaly, presence 2 10.7 30.1 6
Extreme (male, OFC R 63 cm) 0.2 130 160 10
Extreme (female, OFC R 60 cm) 0.2 20 170 10
Lhermitte Duclos disease 0.01 80 860 10
Autism or developmental delay 5 0.2 1.2 1
Breast and Gynecological
Invasive breast cancer
<30 0.06 23.3 23.3 4
30–39 0.43 20.2 19.8 4
40–49a 1.45 17.3 12.6 2
R50 10.93 3 1.8 1
Fibrocystic breast disease 10 4.5 4.2 1
Endometrial cancer
20–29 0.01 50 140 10
30–39 0.06 20 46.7 6
40–49 0.19 13.7 36.8 6
R50 2.43 3.7 2.9 1
Fibroids 13 3.2 2.9 1
Gastrointestinal
Polyposis syndrome
(five or more, any type)
1 3.7 34.3 6
Intestinal hamartoma or
ganglioneuroma, any number
0.01 10
Glycogenic acanthosis 0.01 100 1520 10
Skin
Trichilemmomas,
biopsy proven
0.01 60 570 10
Oral papillomas 0.46 17.4 33 6
Penile freckling 1 18.8 29.4 6
Acral keratoses 10 0.6 2.7 1
Arteriovenous
malformations
0.25 3.6 45.6 6
Skin lipomas 20 1.3 2.1 1
Endocrine
Thyroid cancer
<20 0.01 90 480 10
20–29a 0.06 46.7 48.3 4
30–39a 0.13 44.6 51.5b 4
40–49a 0.17 43.5 44.7 4
R50a 0.57 17.7 6.7 1
(Continued on next page)
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Table 4. Continued
Population Risk
Relative Risk
(Referral/Community)
Relative Risk
(Mutants/Community) Weight
Thyroid goiter, nodules,
adenomas, or Hashimoto’s
thyroiditis (one or more features)
5 7.1 14.4 4
Genitourinary
Renal cell carcinoma 1.49 3.2 4.5 1
a For these specific features, referral bias was clinically recognized and accounted for by a standard downward modification of weight by a risk tier; this bias may
also be recognized in a high RR (study population/community, relative to the RR in patients with PTENmutations/community). Individual features for which high
referral bias was evident, but where weight was already 1, were not further adjusted downward.
b For this borderline RR just above the threshold of 50, given the relatively consistent RRs in adjacent groups for all populations, this weight was adjusted to 4 for
consistency between the adjacent age groups.significance, whereas no significant overall difference was
seen for P-MAPK1/P-MAPK2, actin, or GAPDH. It was
noted on inspection that PTEN and P-AKT1 protein expres-
sion for the rare PTEN variants was intermediate between
that of mutant and wild-type samples, although there
was no statistical significance discerned between the
protein profiles of rare variant lymphoblasts (n ¼ 15) and
the other groups of samples.
Finally, we evaluated whether an association existed
between PTEN/P-AKT1 protein expression and CC score,
which might serve as a potential index of phenotypic
load of syndromic features. When analyzing the full data
set, a strong inverse association was apparent between
PTEN protein expression and CC score (p < 0.001;
Figure 6). This association remained (p ¼ 0.036) after
excluding patients with pathogenic mutations (Figure 7).
No correlation between P-AKT1 and CC score was noted
in any subgroup of individuals.Discussion
The criteria described here represent the collective experi-
ence derived from the largest prospective cohort ofFigure 2. CC Score Nomogram for Obtaining a Corresponding Ind
The CC score is first derived by a sum of the weights of positive featur
are presented, each corresponding to a CC score of 5 points, 10 points
at age 55 (1 point), with background of thyroid cancer at age 44 (4 po
1%. Case 2 may present with breast cancer at age 38 (4 points) and
corresponding point probability of 3%. Case 3 may present with a s
endoscopy, Hashimoto’s thyroiditis (4 points), and lipomas (1 point),
The Apatients with germline pathogenic PTEN mutations to
date (290 probands) with standard-of-care testing. This
represents a core strength of this study. To our knowledge,
outside of these two specialist centers, the largest single re-
ported series from a single center includes 21 patients,35
and, to date, a total of 211 patients (both probands and
affected family members) have been reported in the entire
published medical literature.35 Our study is limited to
probands only, this being critical for an accurate evalua-
tion of the relative importance of each feature in initial
screening through the reduction of ascertainment bias.
In terms of the mutation spectra, our summary study
confirms our previously reported profiles from smaller
data sets.36Pediatric Criteria
The classification of our recommendations for PTEN
mutation testing into distinct adult and pediatric criteria
has demonstrated considerable clinical utility in our
cohorts. This success is likely multifactorial in nature,
with reasons including age-specific phenotypic pene-
trance and, importantly, the different health services
utilized in the distinct age groups: for example,ividual Point Pretest Probability of Germline PTEN Mutation
es that is provided in Table 4. To illustrate, three hypothetical cases
, and 15 points, respectively. Case 1may present with breast cancer
ints), with a final score of 5 and corresponding point probability <
concurrent macrocephaly (6 points), with a final score of 10 and
ingle hamartomatous gastrointestinal polyp (10 points) found on
for a final score of 15 and corresponding point probability of 10%.
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Table 5. Comparison of the CC Pediatric Criteria and Adult Score Relative to the NCCN 2010 Criteria
Cleveland Clinic Ohio State University
Nonmutant Mutant Nonmutant Mutant
Adult
CC scorea Fails threshold 1426 10 445 8
Meets threshold 476 95 267 102
Sensitivity/specificity 90%/75% 93%/62%
Concordance index 0.83c 0.83c 0.78 0.78
NCCN criteriab Fails criteria 1310 27 474 17
Meets criteria 592 78 238 93
Sensitivity/specificity 74%/69% 85%/67%
Concordance index 0.72 0.72 0.76 0.76
Pediatric
CC criteriaa Fails threshold 6 0 7 1
Meets threshold 58 28 68 46
Sensitivity/specificity 100%/10% 98%/9%
NCCN criteriab Fails criteria 5 3 56 20
Meets criteria 59 25 19 27
Sensitivity/specificity 89%/8% 56%/74%
Overall
CC scorea Fails threshold 1432 10 493 11
Meets threshold 533 124 294 146
Sensitivity/specificity 93%/73% 93%/63%
Concordance index 0.83c 0.83c 0.76 0.76
NCCN criteriab Fails criteria 1315 30 530 37
Meets criteria 650 104 257 120
Sensitivity/specificity 78%/67% 76%/67%
Concordance index 0.72 0.72 0.72 0.72
a For adults, using a threshold Cleveland Clinic (CC) score of 10 points and above for recommendation of PTEN testing.
b National Comprehensive Cancer Network (NCCN) criteria, 2010.
c Optimism corrected with 200 bootstraps.macrocephaly and delayed development are well-estab-
lished clinical problems for pediatricians who use head
circumference measurements routinely, whereas cancers
and polyps are common presenting problems in adult
medicine. Indeed, it is possible that patients who
present in childhood are more readily identified than
adult patients, given that features such as macrocephaly
and autism are likely to result in early consults with
pediatricians, who are often familiar with issues of
genetics. At the same time, patients presenting and
being diagnosed during adulthood with PTEN mutations
tend to have fewer overt disease manifestations because
of many reasons, including a selection bias, in which
more severely affected individuals may already have
been diagnosed during childhood, true age-related pene-
trance, and less physician familiarity. In terms of the50 The American Journal of Human Genetics 88, 42–56, January 7, 20phenotypic spectrum, the particularly high prevalence
of neurologic features such as autism and develop-
mental delay (>80%) validate early observations by
our group,13 demonstrating previously unrecognized
PTEN mutations in patients with autism spectrum
disorder and macrocephaly. The inclusion of this feature
into our clinical criteria is particularly noteworthy,
because autism was not hitherto recognized in pediatric
patients with BRRS, and germline PTEN mutation is
now recognized as one of the most common single
gene causes of autism.26,37 Thus, the pediatric CC
criteria that we have developed de novo here, maxi-
mizing sensitivity, represents an important guideline
for pediatricians to select children for referral to genetic
professionals for PTEN mutation testing. Such an
approach is aided by the routine use of head11
Figure 3. A Calibration Plot for Model-Based Predicted Proba-
bilities of PTEN Mutation and Actual Outcomes
The calibration plot shows excellent bias-corrected correlation
between observed and predicted values for the developed model
within the CC data set, suggesting good internal calibration for
the CC score model, that is, individual predicted and actual
outcomes are similar. The dashed line at 45 (y ¼ x) represents
ideal agreement between observed and predicted probabilities of
PTEN mutation.circumference measurements, and this macrocephaly is
present in all patients diagnosed in childhood. Indeed,
because macrocephaly is similarly present in almost allThe Aadult patients, it is likely that active evaluation of pedi-
atric patients with macrocephaly may result in earlier
diagnosis.Adult Clinical Scoring
For adult patients, our study establishes useful clinical
thresholds that can be readily translated to community
practice for referral of patients for specialist evaluation.
We recommend a threshold CC score of 10 (or a point
pretest probability of 3%) and above for referral to medical
genetics for specialist evaluation, this permitting a sensi-
tivity of at least 90%. We present a range of scenarios
that would satisfy this threshold. It is clear that age of
presentation for cancer profoundly influences risk:
patients presenting with endometrial, thyroid, or breast
cancer below the age of 40 must be evaluated for other
suggestive features of germline PTEN mutation, particu-
larly macrocephaly. For patients presenting with first onset
of cancer above 40, combinations of the above cancers,
together with other suggestive nonmalignant features,
are more common. Similarly, gastroenterologists or
surgeons who encounter patients with polyposis
syndromes (at least five polyps) should also assess the
past medical history of these individuals for the presence
of other types of cancer, particularly breast, endometrial,
or thyroid cancer, or relevant combinations. TheseFigure 4. A Graph Showing that the CC
Score Yields Superior Predictions Relative
to the NCCN Criteria in Both the CC and
the OSU Data Sets
Each data set shows corresponding likeli-
hood ratio chi-squares for the NCCN
criteria, the CC score, and a full model
comprised of both criteria. The CC score
confers statistically significant benefit to
the NCCN criteria in PTEN mutation
prediction, but the NCCN criteria do not
confer benefit to the CC score. Higher
adequacy indices are observed for the CC
score relative to the NCCN criteria in
both data sets.
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Figure 5. Bar Plot Showing Expression
by Immunoblot of Downstream Readout
Molecules of PTEN Function for Immortal-
ized Lymphoblasts from 423 Patients
A statistically significant decrease in PTEN
protein expression and increase in phos-
pho-AKT1 expression are noted for
samples with pathogenic mutations. Stan-
dard errors are shown in the error bar.
P values are derived from ANOVA testing.scenarios are useful, given that PTEN mutation will be
considered in the majority of adult patients only after
the diagnosis of cancer or polyposis syndrome. Similarly,
based on our results, we would recommend consideration
of PTEN mutation analysis in patients with documented
vascular malformations as defined by ultrasound evalua-
tion38 as an important feature of adult PHTS. This feature
is recognized in BRRS as an important component of the
syndrome, but it is not part of the NCCN diagnostic
criteria, even though vascular malformations have been re-
ported in association with CS since the 1970s.39
For adult patients seen by front-line clinicians, genetic
etiologies are most often considered if a patient presents
with a serious disorder under the age of 40. This common
clinical approach for referral of such patients for genetics
evaluation is supported by our results, which show that
PTEN mutation should be considered particularly in
patients with breast or endometrial cancer with onset
below the age of 40, as well as thyroid cancer with onset
below age of 50. However, a not-insignificant proportion
of our patients did present with cancer with first onset
above age 40, as seen in Table 2. For such patients with
late onset of cancer, a majority has distinct phenotypic
features or cancer combinations such as breast and thyroid
cancers or thyroid and endometrial cancers, which
certainly should mandate clinical evaluation. For such
individuals, we have demonstrated previously that head
circumference measurement alone in the setting of a
high-risk breast cancer clinic population was useful in
identifying patients with germline PTEN mutation.40 For
these patients who are often first recognized by gastroen-
terologists or surgeons, we also recommend evaluation by
genetics professionals, whichmay also be useful for consid-
eration of other polyposis syndromes. Indeed, our criteria52 The American Journal of Human Genetics 88, 42–56, January 7, 2011here underline our recent report that
PTEN mutation may also underpin
a distinct gastrointestinal polyposis
phenotype in adults,14 to be consid-
ered alongside other polyposis
syndromes such as familial adenoma-
tous polyposis and Peutz-Jeghers
syndrome. We have demonstrated
that the measurement of head
circumference is a useful clinical
maneuver to facilitate diagnosis in
these patients.14 Although colorectalcancer is recognized in association with PTENmutation,14
it does not confer sufficient additional diagnostic value in
the community setting.
Advantages of Clinical Scoring over Existing Criteria
The semiquantitative CC score has several advantages over
the NCCN criteria. First, the CC score is more accurate and
can provide individualized estimates of probability. In
particular, the ability to quantify these probabilities is crit-
ical for an educated discussion between patients and
healthcare providers. Further, adoption of quantitative
risk assessment by health management organizations in
genetic screening policies underlines their importance.
The CC score permits a corresponding estimate for the use
of specialist genetics staff and represents a tool for individ-
ualized counseling and testing of patients with the wide
variety of phenotypes that CS represents. Second, because
of the complex and multisystem nature of CS, the current
NCCNcriteria involve complex rules involvingmultiplicity
of combinations betweenmajor andminor criteria inacces-
sible to most clinicians. A clinical score, represented by
a single number as a sum of weights, can be calculated rela-
tively simply. Third, we have found that the age of onset for
cancer in patients is crucial for clarifying the diagnosis, and
this has been readily incorporated. Finally, accrued clinical
experience, togetherwith our active recruitment of patients
from the community, demonstrated that certain dermato-
logic features of CS patients, although characteristic to the
eye of the trained specialist, were much more challenging
to apply to the community setting.41
Performance
Although it was clear that the CC score outperformed the
NCCN criteria, it is of interest that the fraction of adult
Figure 6. The Relationship between the CC Score and PTEN
Protein Quantitation
This relationship between CC score and PTEN protein levels is
classified by quintiles, lowest to highest from left to right of
each graph, with an inverse association that is demonstrated
between rising PTEN protein expression and decreasing mean
CC score in the full data set on linear regression (p < 0.001). Stan-
dard errors are shown by error bar.
Figure 7. The Relationship between the CC Score and PTEN
Protein Quantitation after Exclusion of Patients with PTEN Muta-
tions
The relationship between CC score and PTEN expression levels is
classified by quintiles, lowest to highest from left to right of each
graph. An inverse association between rising PTEN protein
expression and decreasing CC score is seen in samples derived
from patients without pathogenic germline PTEN mutations
(p ¼ 0.036). Standard errors are shown by error bar.patients with PTENmutations in the CC and OSU cohorts
is relatively low (7.6%). Certainly the relaxed recruitment
criteria (any two features) for recruitment with the goal
of detecting more subtle phenotypes were likely to be the
main reason. The strictly applied ICC/NCCN criteria,
which we first developed on early consortium data based
on a retrospective and cross-sectional series, were previ-
ously reported to result in a high PTENmutation frequency
(85%). Based on this study, it is now clear that the ICC/
NCCN criteria have a lower positive predictive value of
15%–30% in a prospective setting, where patients are
accrued in a setting closer to the community. That germ-
line alterations of other genes may contribute to this
phenotype is of considerable interest, and we have previ-
ously identified germline SDHB and SDHD mutations in
10% of research participants with a similar clinical pheno-
type and without germline PTEN mutations.22 Further-
more, we have recently identified ~35% of individuals,
who have similar clinical phenotypes but without PTEN
mutations, with germline hypermethylation of the
KILLIN-PTEN bidirectional promoter resulting in downre-
gulation of KILLIN.42
Molecular Correlates of Clinical Score
In addition to the clinical dimension of a disease, useful
clinical scoring should also reflect biological andmolecular
aspects of the disease. Experimental data from nonhuman
models has accrued, supporting the molecular concept of
subtle variations of Pten protein dosage deficiency as
a key influence on carcinogenesis, with a Pten dose reduc-The Ation of 20% associated withmanifestation ofmurine breast
cancer and altered steady-state biology of mammary
tissue.16 Our study provides direct support from human
clinical data for the idea that PTEN protein dosage may
influence a multisystem phenotype, showing that the
molecular phenotype of PTEN protein deficiency is corre-
lated with increased CC score and consequently increased
CS phenotypic load. Thus, even though the average
decrease of PTEN protein is relatively subtle, its correlation
with PTEN mutation and elevated CC score is highly
provocative in light of these insights. Although the mech-
anisms of this dose reduction remain unclear, possible
explanations include hereditary variants in other genes
that regulate PTEN expression or its localization.43–45 It is
also possible that extended upstream PTEN promoter
variants may affect this expression. Either way, our results
imply that phenotypes comprising a complex multisystem
syndrome may be underpinned by more genetic variation
than would be expected, manifesting in a common PTEN
protein deficiency pathway with a genetic basis. The
provocative idea that PTEN protein deficiency may
underpin a pathogenic clinical phenotype, however,
requires additional validation. When evaluating other
proteins that are downstream readouts of the PTEN
signaling pathway, the increased expression of phospho-
AKT1 in PTEN-mutated samples is expected.46 The absence
of association between phospho-MAPK1/2 protein
expression and PTEN protein expression or mutant status,
as would be expected,19 requires additional investigationmerican Journal of Human Genetics 88, 42–56, January 7, 2011 53
of the relative impairments of the lipid and protein phos-
phatase activities of the mutations. Overall, our results
highlight that the CC score, in correlation with protein
quantitation, represents a novel resource for the in-
terrogation of PTEN function in the clinical setting, consis-
tent with the ‘‘phenomic’’ approach we have previously
advocated.21
In terms of limitations, our data are derived from two
referral cohorts representing patients recruited at two
major cancer genetics centers, with consequent possible
referral bias. It is also likely that referral bias for certain clin-
ical features (particularly adult cancers) may result in over-
representation of certain patient groups in our patient
cohort. We have described our method to adjust for this
referral bias through the reduction of score weightage for
these features. The most important test of this model and
adjustment approach for referral bias is whether it may
be validated externally. We were able to demonstrate excel-
lent performance through both calibration and external
validation, demonstrating that the approach we have
undertaken performs well in a prospective real-world
setting. Until a population-based sampling approach to
screen community patients for CS is performed, our
approach represents the best available evidence-based clin-
ical approach to identifying patients with germline PTEN
mutations, over the current NCCN criteria. Most impor-
tantly, its excellent performance in the real-world setting
that we have validated here implies that it is of practice-
changing importance.
Overall, we have developed a useful semiquantitative
scoring system to evaluate patients for the prior probability
of PTEN germline mutations, validated in two large sepa-
rate prospective cohorts, representing an evidence-based
advance on existing NCCN criteria. We make practice
recommendations with regard to the evaluation of patients
for germline PTEN mutations, guided by the data accrued
above. Additionally, in demonstrating correlation between
this score and PTEN protein expression in immortalized
lymphocytes, we provide direct support from clinical
studies for the concept of gene dosage for PTEN, high-
lighting the contribution of PTEN protein deficiency to
the complex phenotypic features recognized in CS.Supplemental Data
Supplemental Data include two figures and two tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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